A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- How Guardant aims to expand cancer screening with a blood test (Medtech Dive)
- Endoscope manufacturer faces $1M lawsuit after demo explosion (Becker’s GI & Endoscopy)
- AI-Based Red Density Score Predicts Clinical Outcomes in Ulcerative Colitis (GI & Endoscopy News)
- Machine Learning Improves Accuracy of Inflammatory Bowel Disease Identification Beyond ICD-10 Codes (Houston Methodist)
- No Surprises Act payment dispute process booms to $22.4 billion cost in 4 years: study (Medical Economics)
- PENTAX Medical and MAGENTIQ EYE Expand Global Partnership to Advance AI-Assisted Colonoscopy Worldwide (PR Newswire)
- Following Their Own Advice? Medscape Gastroenterologist Mental Health & Well-Being Report 2026 (Medscape)
- In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial (GUT)
